<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677688</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/10/06-X</org_study_id>
    <nct_id>NCT02677688</nct_id>
  </id_info>
  <brief_title>Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)</brief_title>
  <acronym>LUPUS CTL EBV</acronym>
  <official_title>Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EBV has been implicated in pathogeny of SLE with increase in EBV sero-prevalence, defective&#xD;
      control in EBV infection and altered both B and T immune responses to this virus The main&#xD;
      objective of this pilot proof-of-concept (POC) study is to evaluate safety and efficacy of&#xD;
      autologous EBV specific CTL adoptive transfer in adult patients with serologically active SLE&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus is a disabling disease of the young woman, whose treatment is based on the&#xD;
      long-term corticosteroid, anti-malarials and immunosuppressants synthesis. This support is&#xD;
      not without potential side effects. EBV is a herpes causes infectious mononucleosis virus,&#xD;
      usually encounter in childhood or adolescence, and that our natural immunity cell (CD8 T&#xD;
      cells) controls all our lives, not eliminate.&#xD;
&#xD;
      Increasingly scientific studies show that there are patients with systemic lupus (and&#xD;
      multiple sclerosis), a failure of self-control of the EBV virus, by T lymphocytes (CD8). This&#xD;
      uncontrolled virus then stimulate the B lymphocytes, which produce antibodies, toxic in&#xD;
      lupus. The laboratory isolate T cells specific for EBV (EBV-CTL) of a patient, and stimulate&#xD;
      in culture to strengthen them. They can be then re-injected by a single intravenous infusion&#xD;
      (autotransfusion), and were used to control the virus in certain diseases where EBV has a&#xD;
      demonstrated role post-transplant lymphoproliferative disorder, chronic fatigue syndrome&#xD;
      EBV-induced.&#xD;
&#xD;
      Our therapeutic approach is completely innovative, as based on the principle of cell therapy,&#xD;
      thus not using new drugs, and based on the restoration of the patient's immune system,&#xD;
      specific EBV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>description of adverse events according CTC toxicity criteria .</measure>
    <time_frame>month 12</time_frame>
    <description>Tolerance will be assessed by clinical and laboratory examinations to each Visit according to CTC toxicity criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus clinical activity</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>Composite Response of SLE Index (Systemic Lupus Erythematosus Responder Index: Systemic Lupus Erythematosus Disease Activity Index + British Isles Lupus Assessment Group + Physician Global Assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, The Short Form (36) Health Survey</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>The Short Form (36) Health Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lupus Quality of Life</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>Lupus Quality of Life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus biological activity (1)</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>biological parameter measurement biomarkers C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus biological activity (2)</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>biological parameter measurement biomarkers C4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus biological activity (3)</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>biological parameter measurement biomarkers anti-dsDNA antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus biological activity (4)</measure>
    <time_frame>day 0, day 10, week 4, month 3, month 6, month 9 and month 12</time_frame>
    <description>biological parameter EBV blood load</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Serologically Active Adult Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Autologous EBV specific CTL infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous EBV specific CTL infusion</intervention_name>
    <arm_group_label>Autologous EBV specific CTL infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  4 systemic lupus criteria of the American College of Rheumatology with antinuclear&#xD;
             antibodies&gt; 1:80&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Lupus serologically active without active serious disease (Kidney, CNS)&#xD;
&#xD;
          -  Anti-native DNA Ac positive and / or C3 or C4 low&#xD;
&#xD;
          -  SLEDAI greater than or equal to 2 at baseline&#xD;
&#xD;
          -  Serology HBV, HCV, HIV, HTLV-1, syphilis: Negative J-30 before sample&#xD;
&#xD;
          -  Hemoglobin &gt;11g/dL&#xD;
&#xD;
          -  Prednisone dose &lt;15 mg / day with a stable dose within 30 days previous injection&#xD;
&#xD;
          -  Immunosuppressive treatments which dosage has not been increased for at least 3 months&#xD;
             before enrollment&#xD;
&#xD;
          -  Agreement telephone and / or mail for coordinating investigator inclusion&#xD;
&#xD;
          -  Social ensured Patient&#xD;
&#xD;
          -  EBV positive serology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evolving severe lupus, requiring high dose corticosteroids and / or immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Predicted Failure to monitoring compliance with impossibility&#xD;
&#xD;
          -  Infectious Episode underway&#xD;
&#xD;
          -  Evolutionary Cancer&#xD;
&#xD;
          -  Risk of death within 6 months&#xD;
&#xD;
          -  Consent Refusal&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hamidou, PU PH</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes - Dermatologie</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Médecine interne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La pitié Salpétriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>autologous anti-EBV CTL</keyword>
  <keyword>adoptive therapy</keyword>
  <keyword>phase 1 -2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

